Lacosamida Fresenius Kabi

Lacosamide, the active ingredient in Lacosamida Fresenius Kabi, is a sodium channel blocker presented as an intravenous solution for intravenous use. It is indicated for the treatment of partial‑onset seizures and is employed as adjunctive therapy in patients with epilepsy.

GNH USA supplies Lacosamida Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing products sourced from the European Union market. Our distribution network ensures timely delivery and regulatory compliance across multiple regions.

Lacosamide is an antiepileptic agent that modulates neuronal excitability in seizure disorders.

- Partial‑onset seizures: Reduces seizure frequency when added to existing antiepileptic regimens. - Adjunctive therapy for epilepsy: Improves overall seizure control in patients with refractory focal seizures. - Focal seizures: Provides additional seizure suppression as part of combination therapy.

Lacosamide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness: A sensation of light‑headedness or unsteadiness. - Nausea: Mild to moderate upset stomach. - Headache: Pressure or throbbing pain in the head. - Fatigue: Unusual tiredness or lack of energy. - Diplopia: Temporary double vision. - Somnolence: Increased sleepiness during the day.

Serious or Rare Side Effects: - Cardiac conduction abnormalities: Prolongation of PR interval or atrioventricular block. - Suicidal ideation: Emergence of thoughts of self‑harm. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hypersensitivity: Rash, angioedema, or anaphylactic reactions. - Respiratory depression: Marked reduction in breathing effort, especially when combined with other CNS depressants.

Before initiating therapy, clinicians should consider several safety aspects related to lacosamide.

- Cardiac monitoring: Obtain baseline ECG and monitor PR interval during treatment. - Renal impairment: Adjust dose in patients with reduced creatinine clearance. - Hepatic impairment: Use caution and consider dose modification in severe liver disease. - Concomitant CNS depressants: Monitor for additive sedation or respiratory depression. - Pregnancy and lactation: Safety data are limited; weigh potential benefits against unknown risks. - Store at ambient temperature: Keep in the original container, protect from light and moisture.

Lacosamide can interact with other medicines, influencing its safety or effectiveness.

Major Interactions (Avoid): - Other sodium‑channel blockers (e.g., carbamazepine, phenytoin): May increase risk of cardiac conduction disturbances. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): Can raise lacosamide plasma concentrations.

Moderate Interactions (Monitor Closely): - Concomitant anticholinergic agents: May exacerbate cognitive side effects. - CNS depressants (e.g., opioids, benzodiazepines): May enhance sedation and respiratory depression. - Diuretics: May affect electrolyte balance, influencing cardiac safety.